Mechanism of AMPK Suppression of LXR-dependent Srebp-1c Transcription by Yap, Fuichi et al.
Int. J. Biol. Sci. 2011, 7 
 
 
http://www.biolsci.org 
645 
I In nt te er rn na at ti io on na al l   J Jo ou ur rn na al l   o of f   B Bi io ol lo og gi ic ca al l   S Sc ci ie en nc ce es s   
2011; 7(5):645-650 
Short Research Communication 
Mechanism of AMPK Suppression of LXR-dependent Srebp-1c Transcription 
Fuichi Yap, Lauren Craddock, and Jian Yang 
 
Department of Physiology, University of South Alabama College of Medicine, Mobile, Alabama 36688.  
 Corresponding author: Jian Yang, Ph.D., Department of Physiology, MSB 3074, 307 University Boulevard, Mobile, Ala-
bama 36688-0002. Phone: (251) 460-6814; Fax: (251) 460-6386; E-mail: jyang@usouthal.edu 
© Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/ 
licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. 
Received: 2011.03.04; Accepted: 2011.05.13; Published: 2011.05.19 
Abstract 
Activation of AMP-activated protein kinase (AMPK) inhibits hepatic fatty acid synthesis 
by suppressing sterol regulatory element-binding protein (SREBP)-1c, a master regulator 
of hepatic lipogenic gene expression. Using a model cell line rat hepatoma McA-RH7777 
(CRL-1601)  that  mimics  the  behavior  of  the  intact  liver  by  producing  high  levels  of 
SREPB-1c mRNA and protein, we previously showed that AMPK suppresses hepatic 
Srebp-1c transcription by inhibiting endogenous liver X receptor (LXR) ligand production 
and  SREBP-1c  processing.  However,  whether  AMPK  directly  inhibits  ligand-induced 
LXR activity remained undetermined. In this study we used a series of mutant Srebp-1c 
promoter linked to a luciferase reporter to determine the inhibitory mechanism in rat 
hepatoma McA-RH7777 cells. AMPK activation by either AICAR or metformin decreases 
Srebp-1c promoter activity by about 75%. Normally, the synthetic LXR ligand T0901317 
compound increases the wild-type Srebp-1c promoter activity by about 3-fold, which is 
similar to that observed in the presence of AICAR or metformin. When endogenous LXR 
ligand production was blocked by the potent HMG CoA reductase inhibitor compactin, 
T0901317-induced Srebp-1c promoter activity was decreased by AICAR or metformin 
treatment. In the mutant Srebp-1c promoter in which two LXR elements are intact but the 
sterol regulatory element (SRE) is disrupted, the fold inductions of the promoter activity 
by T0901317 without AMPK activators are significantly higher than those with AMPK 
activators. Furthermore, AMPK activation attenuates induction of endogenous SREBP-1c 
mRNA by T0901317. These results indicate that AMPK directly inhibits ligand-induced 
LXR activity in addition to blocking production of endogenous LXR ligands. 
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Introduction 
The  5’  adenosine  monophosphate  (AMP)- 
activated protein kinase (AMPK) is a heterotrimeric 
enzyme complex consisting of a catalytic subunit (α) 
and two regulatory subunits (β and γ) [1]. Activation 
of AMPK requires phosphorylation of threonine 172 
(T172) in the catalytic (α) subunit by one of the three 
upstream  kinases,  liver  kinase  B1  (LKB1)  [2-4],  cal-
modulin-dependent protein kinase kinase (CaMKK)-β 
[5-7],  or  transforming  growth  factor-β 
(TGFβ)-activated kinase-1 (TAK1) [8]. AMPK inhibits 
hepatic  fatty  acid  synthesis  [9].  One  of  the  mecha-
nisms  is  suppression  of  sterol  regulatory  ele-
ment-binding protein 1c (SREBP-1c) [10-14], a master 
regulator of hepatic lipogenic gene expression [15].  
SREBP-1c is regulated at both transcriptional and 
posttranslational  levels.  At  transcriptional  level, 
Srebp-1c  promoter  contains  at  least  four  DNA  ele-
ments (LXR responsive element or LXRE, NFY, SRE, 
and  Sp1  element),  which  bind  to  liver  X  receptors 
(LXR), nuclear factor-Y (NF-Y), SREBP, and Sp1, re-
spectively  [16,17].  Srebp-1c  transcription  is  greatly 
stimulated by insulin [18]. Insulin activates Srebp-1c 
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promoter primarily by increasing the activity of LXR, 
whereas SREBPs and NFY play permissive roles [17].  
In  a  recent  study  [19],  we  demonstrate  that 
AMPK  suppresses  SREBP-1c  mRNA  expression  by 
inhibiting  LXR-dependent  Srebp-1c  transcription  via 
inhibition of endogenous LXR ligand production and 
by inhibiting SREBP-1c processing in a model cell line 
–  rat  hepatoma  McA-RH7777  (ATCC  Number 
CRL-1601) that mimics the behavior of the intact liver 
by  producing  high  levels  of  SREBP-1c  mRNA  and 
protein  [20].  However,  whether  AMPK  directly  in-
hibits  ligand-induced  LXR  activity  remained  unre-
solved.  In  this  study  we  used  a  series  of  mutant 
Srebp-1c  promoter  linked  to  a  luciferase  reporter  to 
test  this  hypothesis  in  rat  hepatoma  McA-RH7777 
cells. 
Materials and Methods 
Materials.  McA-RH7777  cell  line 
(ATCC#CRL-1601)  was  purchased  from  American 
Type Culture Collection (ATCC, Manassas, VA). Fao 
cell line (Cat# 89042701) was purchased from Sigma. 
Fetal  bovine  serum  (FBS,  Cat.#16000-044)  and 
first-strand cDNA synthesis kit were obtained from 
Invitrogen  (Carlsbad,  CA),  delipidated  FBS 
(Cat.#55-0116) from Cocalico Biologicals (Reamstown, 
PA), Dual Luciferase Reporter Assay System (E1960) 
from  Promega  (Madison,  WI), 
5’-aminoimidazole-4-carboxamide-1-β-D-ribofuranosi
de  (AICAR,  Cat.#A611700)  from  Toronto  Research 
Chemicals,  metformin  (Cat.#D5035),  compactin 
(Cat.#M4667),  and  1x  PBS/Tween  20  (PBST)  from 
Sigma  (St.  Louis,  MO),  the  synthetic  LXR  ligand 
T0901317 (Cat.#71810) from Cayman Chemical (Ann 
Arbor, MI), RNA STAT-60 from TEL-TEST (Friends-
wood, TX), DNA-freeTM kit from Ambion, 2x SYBR 
Green  Supermix  (Cat.#1708880) from Bio-Rad, BCA 
assay kit from Fisher (Pittsburgh, PA), and FuGENE 6 
transfection  reagent  from  Roche  (Indianapolis,  IN). 
Galacto-Light  Plus  chemiluminescent  reporter  gene 
assay system (Cat.#BL300) was from Applied Biosys-
tems (Bedford, Massachusetts). 
Plasmids.  The  plasmid  pD  containing  the 
wild-type mouse Srebp-1c promoter linked to firefly 
luciferase  reporter  gene  and  the  mutant  constructs 
pM24  (-SRE),  pM31  (-LXRE1,  2),  and  pM34 
(-LXRE1,2/SRE)  were  previously  described  [17,21] 
and kindly provided by Dr. Guoxun Chen (University 
of Tennessee at Knoxville). The plasmid pCMV-β-Gal 
containing the beta-galactosidase reporter gene was 
from Invitrogen (Carlsbad, CA). 
Cell  culture.  McA-RH7777  cells  were  cultured 
and maintained in Medium A (DMEM + 100 units/ml 
of  penicillin  and  100  µg/ml  streptomycin)  supple-
mented with 10% FBS at 37°C in a 5% CO2 incubator 
[19,20].  Fao  cells  were  cultured  and  maintained  in 
Medium B (Kaighn’s Modified Ham’s F-12K medium 
+ 100 units/ml of penicillin and 100 µg/ml strepto-
mycin) supplemented with 10% FBS at 37°C in a 5% 
CO2  incubator  according  to  manufacturer’s  instruc-
tions. 
Transfection of McA-RH7777 cells and lucifer-
ase reporter assay. On Day 0, McA-RH7777 cells were 
plated at density of 5 x 104 cells per well in 24-well 
plates in Medium A supplemented with 10% FBS and 
incubated at 37°C in a 5% CO2 incubator. On Day 1, 
cells were washed with 0.5 ml PBS and 0.5 ml fresh 
Medium A was added to each well before transfec-
tion. Cells were cotransfected with 0.25 μg plasmids 
containing  wild-type  or  mutant  Srebp-1c  promoter 
linked to the firefly luciferase reporter gene and 10 ng 
control  plasmid  pCMV-β-Gal  containing  the  be-
ta-galactosidase  reporter  gene  by  using  FuGENE  6 
transfection  reagent.  Each  transfection  was  done  in 
triplicate wells. Six hours after transfection cells were 
washed with 0.5 ml PBS, switched to Medium A sup-
plemented  with  10%  delipidated  FBS  and  various 
compounds  as  indicated  in  the  figure  legends,  and 
incubated for 16 hours at 37°C and 5% CO2. On Day 2, 
cells were washed with 0.5 ml PBS and firefly lucifer-
ase  activities  were  measured  using  the  Luciferase 
Reporter Assay System and Turner Designs TD-20/20 
Luminometer.  Beta-galactosidae  activity  was  meas-
ured by Galacto-Light Plus chemiluminescent report-
er gene assay system. Firefly luciferase activities in the 
transfected  lysates  were  normalized  by  be-
ta-galactosidase activity or protein concentration from 
the same tube.  
Preparation  of  total  cellular  RNA.  On  Day  0, 
McA-RH7777 cells were plated at the density of 7 x 105 
cells  per  100-mm  dish  and  cultured  in  Medium  A 
supplemented with 10% FBS at 37°C in a 5% CO2 in-
cubator as previously described. On Day 2, cells were 
washed with 1x phosphate-buffered saline (PBS) and 
cultured for 16 h in Medium A supplemented with 
10% delipidated FBS and various compounds as in-
dicated  in  the  figure  legends.  Each  treatment  was 
performed in duplicate dishes. On Day 3, the medium 
was aspirated, the cells in duplicate dishes were har-
vested  and  combined,  and  total  cellular  RNA  was 
prepared with RNA STAT-60 according to manufac-
turer’s instructions.  
Real-time PCR. Real-time PCR was carried out 
as  previously  described  [19].  Briefly,  total  cellular 
RNAs were prepared with RNA STAT-60, and treated 
with  DNase  I  before  cDNA  synthesis.  First  strand 
cDNA was synthesized from 5 μg of DNase I-treated 
total RNA with random hexamer primers by using the Int. J. Biol. Sci. 2011, 7 
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first-strand cDNA synthesis system. Real-time PCR of 
samples was prepared in a final volume of 25 μl con-
taining 50 ng of reverse transcribed total RNA, 167 
nM forward and reverse primers, 12.5 μl of 2x SYBR 
Green Supermix. Real-time PCR was carried out in a 
96-well plate on the iCycler iQ Real-Time Detection 
System (Bio-Rad). All reactions were done in tripli-
cate. The relative amount of all mRNAs was calcu-
lated using the comparative CT method (Applied Bi-
osystem  2001.  User  Bulletin  No.2,  Applied  Biosys-
tems,  Forster  City,  CA).  Ribosomal  phosphoprotein 
36B4 mRNA was used as the invariant control. 
Statistics.  Experimental  data  were  statistically 
analyzed using a two-tailed Student’s t test between 
two means. Results were expressed as mean ± SD. The 
difference between two groups with P<0.05 was con-
sidered to be statistically significant. 
Results and Discussion 
Figure 1 shows a dose curve of the synthetic LXR 
ligand  T0901317  compound  on  the  induction  of 
wild-type  Srebp-1c  promoter  linked  to  a  luciferase 
reporter in the absence or presence of AMPK activa-
tors AICAR and metformin. In the absence of AMPK 
activators,  the  luciferase  reporter  activity  was  in-
creased by 3.3-fold by 0.1 μM T0901317 compound, 
and 3.6-fold by 1 μM. Further increase of T0901317 
concentration did not enhance the promoter activity, 
suggesting that 1 μM reached a saturating concentra-
tion. Activation of AMPK by 0.5 mM either AICAR or 
metformin inhibited the Srebp-1c promoter activity by 
70% and 80%, respectively, consistent with our pre-
vious results [19]. In the presence of AICAR, T0901317 
compound  induced  Srebp-1c  promoter  activity  by 
4-fold at 0.1 μM and 5-fold at 1 μM, whereas in the 
presence of metformin, T0901317 compound induced 
Srebp-1c  promoter  activity  by  3-fold  at 
0.1 μM and 3-fold at 1 μM. These data 
indicate  that  the  LXR  ligand  T0901317 
induces Srebp-1c promoter activity to the 
same extent with or without activation 
of AMPK under normal conditions.  
 
 
Fig. 1. AMPK activation suppresses LXR 
ligand-mediated  induction  of  Srebp-1c 
promoter activity in McA-RH7777 cells. 
A,  Diagram  of  plasmids  containing  the 
wild-type  or  mutant  mouse  Srebp-1c 
promoter linked to the firefly luciferase 
reporter  gene.  B,  Luciferase  reporter 
assay. On Day 0, McA-RH7777 cells were 
plated at density of 5 x 10
4 cells per well in 
24-well plates in Medium A supplemented 
with 10% FBS and incubated at 37°C in a 
5%  CO2  incubator.  On  Day  1,  cells  were 
washed with 0.5 ml PBS and 0.5 ml fresh 
Medium A was added to each well before 
transfection.  Cells  were  cotransfected 
with plasmid D and a control plasmid as 
described in Materials and Methods. Six 
hours  after  transfection,  cells  were 
washed with 0.5 ml PBS, switched to Me-
dium  A  supplemented  with  10%  delipi-
dated FBS and 0.5 mM AICAR or metformin 
or various amounts of T0901317, and in-
cubated for 16 hours at 37°C and 5% CO2. 
On Day 2, cells were washed with 0.5 ml 
PBS, and luciferase and beta-gal activities 
were measured as described in the Mate-
rials  and  Methods.  Normalized  firefly 
luciferase activity without treatment was 
arbitrarily set as 1. Int. J. Biol. Sci. 2011, 7 
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Fig. 2. Activation of AMPK decreases the fold induction of wild-type and mutant Srebp-1c promoter activities by 
LXR ligand T0901317 in McA-RH7777 cells treated with compactin. McA-RH7777 cells were cultured, transfected, 
and treated with AICAR (0.5 mM) or metformin (0.5 mM) with or without T0901317 (1 μM) in the presence of com-
pactin (50 μM compactin + 50 μM sodium mevalonate) as in Fig. 1. Cells were lysed and luciferase reporter assays were 
performed as in Fig. 1 with (A) wild-type Srebp-1c promoter construct pD, (B) pM31 (-LXRE1, 2), (C) pM24 (-SRE), and 
(D) pM34 (-LXRE1, 2/SRE). The value on each column represents the fold change (the average of three assays) as 
compared with control (-AICAR/Metformin/T0901317). White bar, - T0901317; grey bar, + T0901317. *, P<0.05 as 
compared with control (+ T0901317) without AICAR/metformin treatment for each promoter construct. 
 
 
Activation of AMPK is known to inhibit endog-
enous  LXR  ligand  production  by  inhibiting  HMG 
CoA  reductase  activity,  thereby  decreasing  Srebp-1c 
promoter  activity  and  SREBP-1c  mRNA  expression 
[19,20]. There is minimal SREBP-1c mRNA expression 
(<10%  compared  with  control)  in  the  McA-RH7777 
cells  treated  with  compactin,  a  potent  inhibitor  of 
HMG CoA reductase [19]. We carried out luciferase 
reporter assays in the presence of compactin (Fig. 2). 
There  was  negligible  but  detectable  basal luciferase 
reporter  activity  in  the  presence  of  compactin  (Fig. 
2A). Activation of AMPK by AICAR and metformin 
further reduced basal SREBP-1c promoter activity by 
50% and 40%, respectively. In the absence of AMPK 
activators,  T0901317  compound  (1  μM)  increased 
Srebp-1c promoter activity by 10.2-fold. The fold in-
duction by T0901317 compound was reduced to 6.6 in 
the presence of AICAR, and to 7 in the presence of 
metformin. 
These data suggest that activation of AMPK di-
rectly effects ligand-induced LXR activity. However, 
SREBP-1c regulates its own transcription due to the 
presence of the SRE in its promoter; this leads to am-
plification  of  the  LXR  ligand-induced  Srebp-1c  pro-
moter activity [17,22]. To bypass the potential com-
plication  by  this  autoregulation,  we  assayed  three 
mutant  Srebp-1c  promoter  constructs,  pM24  with 
mutation in the SRE, pM31 with double mutations in 
LXRE1 and LXRE2, and pM34 with triple mutations in 
LXRE1, LXRE2, and SRE (Fig. 1A). Fig. 2 shows that 
pM31 (-LXRE1, 2) had about 30% wild-type Srebp-1c 
promoter  activity,  pM24  (-SRE)  had  less  than  15% 
activity, and pM34 (-LXRE1, 2/SRE) virtually had no 
activity, consistent with the published data [17]. For 
the mutant pM31 (-LXRE1, 2), addition of T0901317 
compound (1 μM) did not induce the promoter activ-
ity and AMPK activation did not further decrease the 
mutant promoter activity in the absence or presence 
of T0901317 compound (1 μM). For the mutant pM24 
(-SRE), the fold induction by T0901317 compound was 
28.4 in the absence of AMPK activators, but was sig-
nificantly  reduced  to  13  and  5  in  the  presence  of 
AICAR and metformin, respectively. It is noted that 
activation of AMPK consistently reduced the absolute 
amount  of  T0901317-induced  Srebp-1c  promoter  ac-
tivity with SRE (pD) or without SRE (pM24) (Fig. 2). 
Fig.  3  shows  that  activation  of  AMPK  by  either 
AICAR or metformin attenuated the fold induction of 
SREBP-1c mRNA by T0901317 in McA-RH7777 cells 
treated with compactin, in agreement with the results 
from luciferase reporter assays. Similar results were 
obtained from rat hepatoma Fao cells (Fig. 4). These 
data indicate that activation of AMPK reduces LXR 
ligand-induced Srebp-1c promoter activity when the Int. J. Biol. Sci. 2011, 7 
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endogenous LXR ligand  is  blocked, suggesting  that 
AMPK directly inhibits ligand-induced LXR activity. 
However, because LXR has to form heterodimers with 
retinoid  X  receptor  (RXR)  in  order  to  be  functional 
[23],  our  data  do  not  rule  out  the  possibility  that 
AMPK activation inhibits RXR as well. 
In conclusion, the data from this study support 
the  hypothesis  that  AMPK  inhibits  ligand-induced 
LXR  activity  on  Srebp-1c  promoter.  Further  work 
should  be  conducted  to  determine  whether  AMPK 
directly phosphorylates LXR or RXR and inhibits their 
transcriptional activities. 
 
 
Fig. 3. AMPK activation attenuates the fold induction 
of  endogenous  SREBP-1c  mRNA  by  LXR  ligand 
T0901317 in McA-RH7777 cells treated with compac-
tin.  On  Day  0,  McA-RH7777  cells  were  plated  at  the 
density of 7 x 10
5 cells per 100-mm dish and cultured in 
Medium A supplemented with 10% FBS at 37°C in a 5% 
CO2 incubator. On Day 2, cells were washed with 1x PBS 
and cultured for 16 h in Medium A supplemented with 
10% delipidated FBS and compactin (50 μM compactin + 
50 μM sodium mevalonate) in the absence or presence of 
additional compounds (AICAR, 0.5 mM; metformin, 0.5 
mM;  and  T0901317,  1  μM).  Each  treatment  was  per-
formed in duplicate dishes. On Day 3, cells from dupli-
cate dishes were harvested and combined, total RNA was 
prepared  and  reverse  transcribed,  and  endogenous 
SREBP-1c mRNA levels were measured by real-time PCR 
as described in Materials and Methods. The value on 
each column represents the fold change (the average of 
three  assays)  as  compared  with  control  (-T0901317). 
White bar, - T0901317; grey bar, + T0901317. *, P<0.05 
as  compared  with  control  (+  T0901317)  without 
AICAR/metformin treatment. 
 
Fig. 4. AMPK activation attenuates the fold induction 
of  endogenous  SREBP-1c  mRNA  by  LXR  ligand 
T0901317  in  Fao  cells.  Fao  cells  were  cultured  and 
treated as McA-RH7777 cells in Fig. 3 except that Me-
dium A was replaced with Medium B and the concen-
tration of both AICAR and metformin was 1 mM. Cells 
from  duplicate  dishes  were  harvested  and  combined, 
total RNA was prepared and reverse transcribed, and 
endogenous SREBP-1c mRNA levels were measured by 
real-time PCR as described in Materials and Methods. 
The value on each column represents the fold change 
(the average of three assays) as compared with control 
(-T0901317).  White  bar,  -  T0901317;  grey  bar,  + 
T0901317.  *,  P<0.05  as  compared  with  control  (+ 
T0901317) without AICAR/metformin treatment. 
 
Abbreviations 
AMPK: AMP-activated protein kinase; AICAR: 
5’-aminoimidazole-4-carboxamide-1-β-D-ribofuranosi
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3-hydroxy-3-methylglutaryl coenzyme A; LXR: liver 
X receptor; NFY: Nuclear factor Y; RXR: retinoid X 
receptor;  SREBP:  sterol  regulatory  element-binding 
protein. 
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